Journals / Turkish Journal of Gastroenterology / 2010 / Cilt: 21 - Sayı: 3

Helikobakter pilori eradikasyonunda farklı tedavi protokollerinin etkinliği "son on yıl verilerimiz"

Effectiveness of different treatment regimens in helicobacter pylori eradication: Ten-year experience of a single institution

Pages
218–223
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The eradication rate in the consecutive regimen group (Group 6) did not reach the recommended level (higher than 80-85%).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: We aimed to report the outcomes of different H. pylori eradication regimens used in our institution over the last 10 years.
📊
Key Findings & Data:Subjects were allocated into six groups according to their treatment regimens as follows: Group 1) Proton pump inhibitor, clarithromycin and amoxicillin for 2 weeks; Group 2) Colloidal bismuth subcitrate, metronidazole and tetracycline for 2 weeks; Group 3) ranitidine bismuth citrate, clarithromycin and amoxicillin for 2 weeks; Group 4) Proton pump inhibitor, colloidal bismuth subcitrate, clarithromycin and amoxicillin for 2 weeks; Group 5) Proton pump inhibitor, tetracycline and amoxicillin for 2 weeks; and Group 6) Proton pump inhibitor and amoxicillin for 5 days, followed consecutively by Proton pump inhibitor, clarithromycin and metronidazole for 5 days.
💡
Conclusion & Impact:The eradication rate in the consecutive regimen group (Group 6) did not reach the recommended level (higher than 80-85%).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Zaman faktörleri · İlaç tedavisi · kombinasyon

Abstract

Aim: We aimed to report the outcomes of different H. pylori eradication regimens used in our institution over the last 10 years. Method: Retrospectively, H. pylori-positive patients who were referred for upper gastrointestinal endoscopy with dyspeptic symptoms and who started eradication treatment and returned for a follow-up visit were included in the study. Subjects were allocated into six groups according to their treatment regimens as follows: Group 1) Proton pump inhibitor, clarithromycin and amoxicillin for 2 weeks; Group 2) Colloidal bismuth subcitrate, metronidazole and tetracycline for 2 weeks; Group 3) ranitidine bismuth citrate, clarithromycin and amoxicillin for 2 weeks; Group 4) Proton pump inhibitor, colloidal bismuth subcitrate, clarithromycin and amoxicillin for 2 weeks; Group 5) Proton pump inhibitor, tetracycline and amoxicillin for 2 weeks; and Group 6) Proton pump inhibitor and amoxicillin for 5 days, followed consecutively by Proton pump inhibitor, clarithromycin and metronidazole for 5 days. A follow-up visit to determine eradication was scheduled a minimum of 6 weeks after completion of the treatment. Results: In this study, 400 patients were included. Eradication rates were 74.7%, 92.3%, 81.2%, 81.5%, 70.5%, and 66.6% in Groups 1-6, respectively. Conclusion: In Group 1, the eradication rate was lower than 80%. In Groups 34, the eradication rate increased to over 80%. The colloidal bismuth subcitrate, metronidazole and tetracycline regimen (Group 2) was the most successful, with a rate of 92.3%. The eradication rate in the consecutive regimen group (Group 6) did not reach the recommended level (higher than 80-85%).

Özet

Amaç: Çalışmamızdaki amaç son on yılda farklı tedavi seçenekleri ile H. pilori eradikasyonunda elde ettiğimiz verileri sunmaktır. Yöntem: 1999 ile 2009 yılları arasında dispeptik yakınmaları nedeniyle üst gastrointestinal sistem endokopisine refere edilen, H. pilori pozitif, eradikasyon tedavisi alan ve tedavi sonrası kontrolü yapılan hastalar retrospektif olarak değerlendirildi. Grup-1) proton pompa inhibitörü 2x1, klaritromisin 500 mg 2x1, amoksisilin 1000 mg 2x1, 2 hafta; Grup-2) kolloidal bizmut subsitrat 300 mg 4x1, metronidazol 500 mg 3x1, tetrasiklin 500 mg 3x1 2 hafta süre; Grup-3) ranitidin bizmut sitrat 400 mg 2x1, klaritromisin 500 mg 2x1, amoksisilin 1000 mg 2x1 2 hafta; Grup-4) proton pompa inhibitörü 2x1, kolloidal bismuth subsitrat 300 mg 4x1, klaritromisin 500 mg 2x1, amoksisilin 1000 mg 2x1, 2 hafta; Grup-5) proton pompa inhibitörü 2x1, tetrasiklin 500 mg 3x1, amoksisilin 1000 mg 2x1, 2 hafta; Grup-6) proton pompa inhibitörü 2x1, amoksisilin 1000 mg 2x1/5 gün ve proton pompa inhibitörü 2x1, klaritromisin 500 mg 2x1, metronidazol 500 mg 2x1/ 5 gün süre ile aldılar. Eradikasyon belirlenmesi için kontrol, tedavi bitiminden en erken 6 hafta sonra yapıldı. Bulgular: Çalışmada 400 hasta yer aldı. Eradikasyon oranları sırayla %74.7, %92.3, %81.2, %81.5, %70.5 ve %66.6 olarak saptandı. Sonuç: Grup 1'de eradikasyon oranı %80'den düşük saptandı. Grup 3-4'te başarı %80 üzerine çıktı. Kolloidal bizmut subsitrat, metronidazol ve tetrasiklin (Grup 2) kombinasyonunda %92.5 eradikasyon oranı ile en yüksek başarı elde edildi. Ardışık tedavi (Grup 6) ile eradikasyon oranı kabul edilebilir oranların (>%80-85'ten fazla olması) altındaydı. H. pilori eradikasyonunda %80'nin üzerinde eradikasyon yalnız bizmut içeren 3'lü ve 4'lü tedavilerde elde edilmiştir.

🔖

Cite This Article

ÖZDEN, A., SEVEN, G., BEKTAŞ, M. (2010). Helikobakter pilori eradikasyonunda farklı tedavi protokollerinin etkinliği "son on yıl verilerimiz". Turkish Journal of Gastroenterology, Cilt: 21 - Sayı: 3, 218–223. https://ajindex.com/articles/410346

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-86
  2. Malaty HM, Graham DY. Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut 1994; 35: 742-5
  3. Us D, Hascelik G. Seroprevalence of Helicobacter pylori infection in an asymptomatic Turkish population. J Infect. 1998 Sep; 37: 148-50
  4. Seyda T, Derya C, Fusun A, et al. The relationship of Helicobacter pylori positivity with age, sex, and ABO ⁄ Rhesus blood groups in patients with gastrointestinal complaints in Turkey. Helicobacter 2007; 12: 244-50
  5. Morgner A, Lehn N, Andersen LP, et al. Helicobacter heilmannii associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology 2000; 118: 821-8.6. Dixon MF. Pathology of gastritis and peptic ulceration. In: Mobley HLT, Mendz GL, Hazell SL, eds. Helicobacter pylori: Physiology and Genetics. Washington, DC: ASM Press, 2001: 459-69
  6. Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994; 330: 1267-71
  7. Wotherspoon AC. Helicobacter pylori infection and gastric lymphoma. Br Med Bull 1998; 54: 79-85
  8. Bayerdorffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet 1995; 345: 1591-4
  9. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology. 1996; 110: 1244-52
  10. Malfertheiner P, Me ́graud F, Morain CO, et al. Current concepts in the management of Helicobacter pylori infection. The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80
  11. Vakil N, Lanza F, Schwartz H, et al. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004; 20: 99-107
  12. Kadayifci A, Buyukhatipoglu H, Savas CM, et al. Eradication of Helicobacter pylori with triple therapy: an epidemiologic analysis of trends in Turkey over 10 years. Clin Ther 2006; 2811: 1960-6
  13. Al-Eidan FA, McElnay JC, Scott MG, et al. Management of Helicobacter pylori eradication the influence of structured counselling and follow-up. Br J Clin Pharmacol 2002; 53: 163-71
  14. Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of H. pylori with triple therapy. Gastroenterology 1992; 102: 493-6
  15. Cirak